Search research articles
Contact Us
Filters
Showing results (1-10 of 66) with videos related to
Page
of 7
Sort By:
Annals of Internal Medicine
|
May 1, 2023
In prediabetes, oral vitamin D reduces progression to new-onset diabetes
Darren Lau
Annals of Internal Medicine
|
May 6, 2024
In HFpEF with obesity, semaglutide improved health status and weight loss at 52 wk, regardless of initial health status
Darren Lau
Annals of Internal Medicine
|
June 1, 2026
In T2D inadequately controlled with metformin, orforglipron reduced HbA<sub>1c</sub> more than oral semaglutide at 52 wk
Darren Lau,
Annals of Internal Medicine
|
May 5, 2025
In adults with overweight or obesity and without diabetes, GLP-1 RAs increase weight loss vs. placebo
Darren Lau,
Annals of Internal Medicine
|
October 2, 2023
In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk
Darren Lau
Canadian Journal of Diabetes
|
December 28, 2025
Upstream Delivery of Routine Chronic Kidney Disease Screening for Individuals With Diabetes Is an Impediment to Realizing Cardio-Kidney Care
Darren Lau
Annals of Internal Medicine
|
August 2, 2021
In adults with overweight or obesity, continued weekly semaglutide after a 20-wk run-in improved weight loss
Darren Lau, Raj Padwal
Annals of Internal Medicine
|
October 6, 2025
In T2D and hypertension, the lower-sodium DASH4D diet reduced SBP more than a higher-sodium comparison diet at 5 wk
Darren Lau, Raj Padwal,
Annals of Internal Medicine
|
January 3, 2022
In uninfected household contacts of patients with COVID-19, REGEN-COV reduced symptomatic COVID-19 at 28 d
Darren Lau, Lynora Saxinger
Annals of Internal Medicine
|
August 4, 2025
In insulin-treated T2D, automated insulin delivery reduced HbA<sub>1c</sub> without increasing hypoglycemic events vs. usual care at 13 wk
Darren Lau, Peter Senior,
Page
of 7
Search research articles
Search
Showing results (1-10 of 66) with videos related to
Sort By:
Page
of 7
Annals of Internal Medicine
|
May 1, 2023
In prediabetes, oral vitamin D reduces progression to new-onset diabetes
Darren Lau
Annals of Internal Medicine
|
May 6, 2024
In HFpEF with obesity, semaglutide improved health status and weight loss at 52 wk, regardless of initial health status
Darren Lau
Annals of Internal Medicine
|
June 1, 2026
In T2D inadequately controlled with metformin, orforglipron reduced HbA<sub>1c</sub> more than oral semaglutide at 52 wk
Darren Lau,
Annals of Internal Medicine
|
May 5, 2025
In adults with overweight or obesity and without diabetes, GLP-1 RAs increase weight loss vs. placebo
Darren Lau,
Annals of Internal Medicine
|
October 2, 2023
In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk
Darren Lau
Canadian Journal of Diabetes
|
December 28, 2025
Upstream Delivery of Routine Chronic Kidney Disease Screening for Individuals With Diabetes Is an Impediment to Realizing Cardio-Kidney Care
Darren Lau
Annals of Internal Medicine
|
August 2, 2021
In adults with overweight or obesity, continued weekly semaglutide after a 20-wk run-in improved weight loss
Darren Lau, Raj Padwal
Annals of Internal Medicine
|
October 6, 2025
In T2D and hypertension, the lower-sodium DASH4D diet reduced SBP more than a higher-sodium comparison diet at 5 wk
Darren Lau, Raj Padwal,
Annals of Internal Medicine
|
January 3, 2022
In uninfected household contacts of patients with COVID-19, REGEN-COV reduced symptomatic COVID-19 at 28 d
Darren Lau, Lynora Saxinger
Annals of Internal Medicine
|
August 4, 2025
In insulin-treated T2D, automated insulin delivery reduced HbA<sub>1c</sub> without increasing hypoglycemic events vs. usual care at 13 wk
Darren Lau, Peter Senior,
Page
of 7